Bashir H
Anaesth Intensive Care. 1980 May;8(2):132-8. doi: 10.1177/0310057X8000800206.
Each blood transfusion exposes the recipient to the hazards of immunisation to histocompatibility antigens as well as white cell and platelet antigens. As the number of transfusions received by a patient increases so too does the likelihood of the development of antibodies which may by their multispecific character effectively prevent lifesaving therapy in the future. Special steps can and should be taken to minimise the risks of immunisation in the group of patients who will be dependent on long term transfusion therapy. An extension of knowledge about the antigenic systems of leucocytes and platelets, including HLA, and the introduction of more specific tests for the detection of antibodies directed against them should assist in the provision of more appropriately matched blood components.
每次输血都会使受血者面临对组织相容性抗原以及白细胞和血小板抗原产生免疫反应的风险。随着患者接受输血次数的增加，产生抗体的可能性也会增加，而这些抗体的多特异性可能会在未来有效地阻碍挽救生命的治疗。对于那些依赖长期输血治疗的患者群体，可以而且应该采取特殊措施来尽量降低免疫风险。扩展关于白细胞和血小板抗原系统（包括人类白细胞抗原）的知识，并引入更特异的检测针对这些抗原的抗体的方法，应有助于提供更匹配的血液成分。
